Physician profile
Jack Kanoff
NPI 1902813843
$4,097.19
in general payments reported to CMS, 2019-2025
33 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $375 · 2021: $678 · 2022: $823 · 2023: $365 · 2024: $586 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $782.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $513.31 | 2019-2024 | Breztri, Tezspire, Airsupra |
| Philips North America LLC | $375.96 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $329.33 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $309.54 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $221.12 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $218.03 | 2019-2025 | |
| Mylan Specialty L.P. | $194.30 | 2019-2024 | Yupelri |
| Insmed, INC. | $178.04 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $126.57 | 2021-2024 | |
| Amgen INC. | $106.33 | 2021-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.41 | 2019-2023 | Ofev |
| Verona Pharma, INC. | $72.32 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $70.76 | 2019-2022 | |
| Grifols USA, LLC | $58.40 | 2019-2024 | Prolastin-C Liquid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $56.65 | 2024 | Lumryz |
| Electromed, INC. | $38.25 | 2022-2024 | Smartvest |
| Gilead Sciences, INC. | $34.44 | 2019 | |
| Azurity Pharmaceuticals, INC. | $33.86 | 2024-2025 | Alvesco, Horizant |
| Viatris Specialty LLC | $32.57 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $32.34 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $31.48 | 2019 | |
| Merck Sharp & Dohme LLC | $28.90 | 2022-2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $27.91 | 2022 | |
| Resmed Corp | $21.98 | 2024 | |
| Inspire Medical Systems, INC. | $20.68 | 2024 | Inspire |
| Lilly USA, LLC | $17.58 | 2025 | Zepbound |
| Baxter Healthcare | $15.18 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Vifor Pharma, INC. | $14.70 | 2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.24 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.15 | 2019 | |
| Shire North American Group INC | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Kanoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.